Women With Polycystic Ovary Syndrome Have Increased Plasma Chitotriosidase Activity

March 9, 2012 updated by: Aydogan Aydogdu, Gulhane School of Medicine

Women With Polycystic Ovary Syndrome Have Increased Plasma Chitotriosidase Activity: A Pathophysiological Link Between Inflammation and Impaired Insulin Sensitivity?

In the present study, serum chitotriosidase activity and its relationship with insulin resistance were determined in patients with Polycystic Ovary Syndrome (PCOS).

Study Overview

Status

Completed

Conditions

Detailed Description

ChT activity is increased in patients with PCOS in concordance with insulin resistance. These findings may reflect the pronounced risk for metabolic syndrome and atherosclerotic diseases in this particular patient group.

Study Type

Observational

Enrollment (Actual)

78

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Ankara, Turkey, 06180
        • Gulhane School of Medicine Etlik

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 35 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Sampling Method

Probability Sample

Study Population

34 women with PCOS and 44 healty women as control group.

Description

Inclusion Criteria:

  • Absence of significant abnormalities on physical examination except hirsutism
  • no lipid lowering, hypoglycemic, antihypertensive or hormone replacement therapy
  • normal thyroid function and prolactin level
  • absence of history or evidence of metabolic, cardiovascular, respiratory or hepatic disease

Exclusion Criteria:

  • Pregnant
  • ovarian tumors
  • congenital adrenal hyperplasia or BMI greater than 30 kg/m2

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
PCOS patients
PCOS patients and healthy controls
There are two groups in this study. One group is PCOS patients and other group is healthy controls.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Gulhane School of Medicine

Investigators

  • Principal Investigator: Aydogan Aydogdu, MD, No organizational affiliation

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2010

Primary Completion (ACTUAL)

December 1, 2010

Study Completion (ACTUAL)

December 1, 2010

Study Registration Dates

First Submitted

June 10, 2011

First Submitted That Met QC Criteria

June 24, 2011

First Posted (ESTIMATE)

June 27, 2011

Study Record Updates

Last Update Posted (ESTIMATE)

March 12, 2012

Last Update Submitted That Met QC Criteria

March 9, 2012

Last Verified

December 1, 2010

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1491-81-11/1539-1563
  • Chitotriosidase activity (OTHER_GRANT: 1202-0811)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Polycystic Ovary Syndrome

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe